Advanced search
1 file | 888.77 KB Add to list

What can platinum offer yet in the treatment of PS2 NSCLC patients?: a systematic review and meta-analysis

Author
Organization
Keywords
Chemotherapy, NSCLC, Performance status, Platinum, Doublet, Single agent, CELL LUNG-CANCER, COOPERATIVE-ONCOLOGY-GROUP, PHASE-III TRIAL, GEMCITABINE PLUS CARBOPLATIN, CISPLATIN VS. GEMCITABINE, PERFORMANCE STATUS, RANDOMIZED-TRIAL, SINGLE-AGENT, 1ST-LINE TREATMENT, ELDERLY-PATIENTS

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 888.77 KB

Citation

Please use this url to cite or link to this publication:

MLA
Bronte, Giuseppe et al. “What Can Platinum Offer yet in the Treatment of PS2 NSCLC Patients?: a Systematic Review and Meta-analysis.” CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 95.3 (2015): 306–317. Print.
APA
Bronte, G., Rolfo, C., Passiglia, F., Rizzo, S., Gil-Bazo, I., Fiorentino, E., Cajozzo, M., et al. (2015). What can platinum offer yet in the treatment of PS2 NSCLC patients?: a systematic review and meta-analysis. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 95(3), 306–317.
Chicago author-date
Bronte, Giuseppe, Christian Rolfo, Francesco Passiglia, Sergio Rizzo, Ignacio Gil-Bazo, Eugenio Fiorentino, Massimo Cajozzo, et al. 2015. “What Can Platinum Offer yet in the Treatment of PS2 NSCLC Patients?: a Systematic Review and Meta-analysis.” Critical Reviews in Oncology Hematology 95 (3): 306–317.
Chicago author-date (all authors)
Bronte, Giuseppe, Christian Rolfo, Francesco Passiglia, Sergio Rizzo, Ignacio Gil-Bazo, Eugenio Fiorentino, Massimo Cajozzo, Jan Van Meerbeeck, Cosimo Lequaglie, Daniele Santini, Patrick Pauwels, and Antonio Russo. 2015. “What Can Platinum Offer yet in the Treatment of PS2 NSCLC Patients?: a Systematic Review and Meta-analysis.” Critical Reviews in Oncology Hematology 95 (3): 306–317.
Vancouver
1.
Bronte G, Rolfo C, Passiglia F, Rizzo S, Gil-Bazo I, Fiorentino E, et al. What can platinum offer yet in the treatment of PS2 NSCLC patients?: a systematic review and meta-analysis. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2015;95(3):306–17.
IEEE
[1]
G. Bronte et al., “What can platinum offer yet in the treatment of PS2 NSCLC patients?: a systematic review and meta-analysis,” CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol. 95, no. 3, pp. 306–317, 2015.
@article{7024159,
  author       = {Bronte, Giuseppe and Rolfo, Christian and Passiglia, Francesco and Rizzo, Sergio and Gil-Bazo, Ignacio and Fiorentino, Eugenio and Cajozzo, Massimo and Van Meerbeeck, Jan and Lequaglie, Cosimo and Santini, Daniele and Pauwels, Patrick and Russo, Antonio},
  issn         = {1040-8428},
  journal      = {CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY},
  keywords     = {Chemotherapy,NSCLC,Performance status,Platinum,Doublet,Single agent,CELL LUNG-CANCER,COOPERATIVE-ONCOLOGY-GROUP,PHASE-III TRIAL,GEMCITABINE PLUS CARBOPLATIN,CISPLATIN VS. GEMCITABINE,PERFORMANCE STATUS,RANDOMIZED-TRIAL,SINGLE-AGENT,1ST-LINE TREATMENT,ELDERLY-PATIENTS},
  language     = {eng},
  number       = {3},
  pages        = {306--317},
  title        = {What can platinum offer yet in the treatment of PS2 NSCLC patients?: a systematic review and meta-analysis},
  url          = {http://dx.doi.org/10.1016/j.critrevonc.2015.03.010},
  volume       = {95},
  year         = {2015},
}

Altmetric
View in Altmetric
Web of Science
Times cited: